Why has there been a reduction in the use of extracorporeal membrane oxygenation (ECMO) for treatment of persistent pulmonary hypertension of the newborn (PPHN)?

Updated: Sep 03, 2019
  • Author: Kate A Tauber, MD; Chief Editor: Howard S Weber, MD, FSCAI  more...
  • Print


Several studies demonstrated a reduction in ECMO use from 1990-2000 because of the advancement in the medical management of PPHN, specifically the use of high-frequency ventilation, inhaled nitric oxide (iNO), and surfactant administration. [36, 37] However, since 2000, the number of PPHN cases reported to the ELSO registry has remained relatively stable, ranging from 115 to 157 cases per year, which may demonstrate a plateau in the benefit for medical therapy for PPHN. [38]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!